Medical Information (MI) and Pharmacovigilance (PV) are two closely connected functions within pharmaceutical organizations and Contract Research Organizations (CROs). With a shared focus on patient safety, they work together to support the safe, informed, and appropriate use of medicines. While each function has distinct responsibilities, effective collaboration between MI and PV promotes consistent safety awareness, timely information sharing, and informed internal decision‑making that ultimately protects patient well-being.
The Medical Information team supports the organization by providing scientific and medical information related to pharmaceutical products to healthcare professionals, patients, and internal stakeholders. They serve as a key point of contact for product‑related questions, providing accurate, evidence‑based information to address medical and scientific inquiries.
Medical Information professionals review available data, including approved product information and relevant scientific literature, to develop responses tailored to each inquiry. These responses prioritize accuracy, clarity, and relevance, ensuring that information supports clear understanding of the product while remaining objective and appropriate for the intended audience.
In addition to responding to inquiries, MI team members contribute to the development and maintenance of scientific content used across the organization, including standard response documents and reference materials. MI teams also monitor clinical data, published literature, and product information to ensure that responses remain current and aligned with the latest available evidence.
During routine interactions, the MI team may receive information related to safety concerns, product complaints, or quality issues. When such information is identified, they promptly share the details with the Pharmacovigilance team in accordance with internal processes, enabling appropriate review and follow‑up as needed.
Pharmacovigilance is responsible for overseeing the collection, review, and evaluation of safety information related to medicinal products. It focuses on understanding a product’s safety profile by analyzing data from variety of sources, including internal teams, clinical studies, and post‑marketing experiences.
PV teams manage the intake and assessment of individual safety reports as well as aggregate safety information, to identify patterns or trends over time. Through ongoing evaluation, PV supports internal discussions around potential risks and contributes to activities aimed at monitoring and managing product safety.
Beyond case review, PV also supports broader safety‑related activities, such as safety evaluations and internal reporting. These efforts provide valuable context for understanding both known and potential safety considerations as products are used in real‑world settings.
MI and PV most directly intersect in the identification and exchange of safety‑related information. Because MI regularly engages with healthcare professionals and patients, it can act as an important source of insights related to product use, tolerability, or emerging safety concerns.
When safety‑related information arises during a medical inquiry, MI shares the information with PV for evaluation, allowing PV to include it in ongoing safety review activities. This exchange of information supports broader visibility of safety considerations and helps ensure relevant details are available for internal evaluation.
MI and PV also collaborate to maintain consistency in safety‑related communications. As PV evaluates safety data and internal understandings evolve, MI incorporates relevant updates into scientific content and responses. This helps ensure that information shared both internally and externally remains aligned and accurate.
Effective collaboration between MI and PV is strengthened through regular communication, shared processes, and aligned systems for documenting and exchanging information. Both functions may use common platforms to capture inquiry details and safety‑related data, helping reduce the risk of gaps and supporting transparency.
Ongoing cross‑functional alignment, supported by routine touchpoints and a clear understanding of each team’s role, further enhances this collaboration. This coordination ensures clear pathways for information flow and helps make certain that safety considerations identified in one function are visible and actionable in the other.
At a CRO like Linical, the collaboration between MI and PV supports both client deliverables and patient safety obligations within a CRO environment.
Through this collaboration:
Safety information received via MI (e.g., adverse events from inquiries) is captured and transferred to PV for processing
PV insights support alignment of medical responses with current safety knowledge
Both teams contribute to consistent, compliant communication across client programs
This integrated approach ensures that Linical meets both scientific communication needs and pharmacovigilance requirements while maintaining high standards of patient safety.
Collaboration between MI and PV supports patient safety by increasing awareness of potential safety considerations and enabling informed internal discussions. By combining insights from medical inquiries with broader safety review activities, the organization develops a more comprehensive understanding of how products are used and experienced in real world settings.
Consistent communication of safety information across both functions helps ensure evolving safety knowledge is reflected in internal materials and external responses supporting the appropriate use of medicines. While MI and PV have different distinct responsibilities, their coordinated efforts advance shared goals of quality, consistency, and responsible product use.
Medical Information and Pharmacovigilance serve distinct yet interconnected roles within the organization. MI focuses on addressing medical and scientific inquiries and communicating relevant information, while PV is responsible for the review and evaluating safety data.
Collaboration between these functions supports effective information exchange, consistent safety communication, and informed internal decision making. Together, MI and PV contribute to an integrated approach that enhances understanding of product safety and reinforces the ongoing commitment to patient well-being.
References:
U.S. Food and Drug Administration (FDA)
World Health Organization (WHO)
Author:
Jennifer Ruffin
Pharmacovigilance Operations Assistant